The biotechnology company Medincell has released its CSR report and has anchored its innovation strategy in the global health objectives of the UN.
The biopharmaceutical company Medincell, based in Montpellier and listed on Euronext, has made public its report on social and environmental responsibility for the fiscal year 2024-2025. This document details the company’s strategy aiming to reconcile economic performance with a positive impact on global health by aligning with the United Nations Sustainable Development Goals (SDGs).
In his introduction, CEO Christophe Douat highlights a year of significant progress.
“I am proud to look back on Medincell’s constant commitment to sustainable innovation and our growing impact on global health,” he declared.
He emphasizes a vision where the development of innovative and accessible therapies is the cornerstone of the company’s mission.
A business model aligned with the SDGs
Medincell articulates its strategy around several Sustainable Development Goals. The contribution to SDG 3 (Good Health and Well-being) is illustrated by the success of UZEDY®, its first injectable long-acting treatment for patients with schizophrenia. According to the report, this treatment not only has a direct impact on the health of sick individuals, but also on healthcare systems by reducing costs, which addresses SDGs 10 (Reduced Inequalities) and 11 (Sustainable Cities and Communities).
The patented BEPO® technology is also highlighted for its environmental benefit. By allowing long-acting injectable formulations, it would reduce the amount of active ingredient required compared to an oral treatment, thus limiting the problem of water contamination by pharmaceutical residues (SDG on Clean Water and Sanitation). The company’s commitment is also manifested through strategic partnerships (SDG 17), such as the collaboration with the iM4TB NGO to develop a treatment for tuberculosis.
Social responsibility and ethical governance
Beyond its products, Medincell affirms its commitment to social and governance aspects. The company indicates that it has strengthened its programs in favor of gender equality (SDG 5) and the well-being of its employees (SDG 8). Progress has been made on the environmental front to reduce its carbon footprint, notably through increased use of renewable energies (SDGs 12 and 13).
Governance is presented as the foundation for long-term success, with a reinforcement of expertise and independence in its Board of Directors to ensure ethical decisions and rigorous oversight (SDG 16). Although not yet subject to the European CSRD Directive due to its size, Medincell has chosen to voluntarily adopt reporting inspired by its requirements, in a transparency move. The company’s ESG performance is also evaluated by several non-financial rating agencies such as ISS ESG, which has awarded it the “Prime” status, or EthiFinance.
A future-oriented approach
Building on this assessment, the company looks towards the future and continues to invest in research. Medincell announces the organization of an entirely digital R&D Day on Tuesday, May 12, 2026. The event, titled “From Science to Long Term Value Creation,” will be an opportunity for the company to present its scientific advances and strategic vision to its investors and partners.
The full report and all regulatory information are available on the company’s website (https://www.medincell.com/regulated-information/).
via Press Agence.
